[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"attention-deficithyperactivity-disorder-adhd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:attention-deficithyperactivity-disorder-adhd":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,76,104,133,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100640558","phase-1-cannabigerol-oil-for-adolescents-with-adhd-can-adhd-100640558",false,"NCT07592390","Cannabigerol Oil for Adolescents With ADHD (CAN-ADHD)","Potential Effects of Cannabigerol in Adolescents With Attention-Deficit\u002FHyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial (CAN-ADHD)","CAN-ADHD","Inclusion Criteria:\n\n* Adolescents aged 12 to 17 years\n* Diagnosis of Attention-Deficit\u002FHyperactivity Disorder (ADHD) confirmed using the SNAP-IV (Swanson, Nolan and Pelham Questionnaire, version IV)\n* History of previous treatment with pharmacological or non-pharmacological interventions without significant improvement of symptoms\n* Absence of severe psychiatric disorders or relevant physical comorbidities\n* Ability of the participant and legal guardian to understand study procedures\n* Provision of written informed consent by the legal guardian and assent by the adolescent\n\nExclusion Criteria:\n\n* Use of cannabinoid-based substances (natural or synthetic) within 30 days prior to study initiation\n* History of intolerance or adverse reactions to cannabis-derived compounds (e.g., confusion, paranoia, pruritus, excessive drowsiness, vomiting, diarrhea, or seizures)\n* Presence of any significant physical comorbidity\n* Presence of severe psychiatric disorder not related to ADHD\n* Moderate to severe cognitive impairment\n* Inability or unwillingness to complete study procedures or questionnaires adequately","ALL","12 Years","17 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","This study aims to evaluate the potential effects of full-spectrum cannabigerol (CBG) oil on cognitive and behavioral symptoms in adolescents diagnosed with Attention-Deficit\u002FHyperactivity Disorder (ADHD). ADHD is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity, often associated with impairments in academic, social, and emotional functioning.\n\nThis is a randomized, double-blind, placebo-controlled clinical trial with a parallel design. A total of 60 adolescents aged 12 to 17 years, diagnosed with ADHD and with insufficient response to previous treatments, will be enrolled and randomly assigned to either the intervention group or the placebo group.\n\nParticipants in the intervention group will receive full-spectrum CBG oil (30 mg\u002FmL), administered sublingually, with individualized dosing determined by the study physician and adjusted through weekly monitoring. The placebo group will receive an inert oil matched in appearance and administration conditions.\n\nThe intervention will last for 12 weeks, including in-person clinical assessments at baseline, week 6, and week 12, as well as weekly remote monitoring to assess adherence, safety, and dose adjustments.\n\nPrimary outcomes will include changes in ADHD symptom severity measured by the SNAP-IV scale. Secondary outcomes will assess quality of life, emotional symptoms, sleep patterns, and safety profile.\n\nThis study aims to contribute to the scientific understanding of cannabinoids as a potential therapeutic option for adolescents with ADHD, a population for which current evidence remains limited.",[29],"Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[31,32,33,34],"ADHD","Cannabigerol","Cannabinoids","Adolescents","RECRUITING","2026-05-13",{"date":38,"type":39},"2026-05-18","ACTUAL",{"date":41,"type":22},"2026-05-01",{"date":43,"type":22},"2026-12-18",{"name":45,"class":46},"Universidade do Sul de Santa Catarina","OTHER_GOV",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":47},"100403353","finding-alternatives-to-standard-treatment-for-attention-deficit-hyperactivity-disorder-100403353","NCT04532190","Finding Alternatives to Standard Treatment for Attention-Deficit Hyperactivity Disorder","FAST-ADHD","Inclusion Criteria:\n\n1. Diagnosis of ADHD\n2. 9-15 years old\n3. IQ greater than 80\n4. English fluency (to enable consent\u002Fassent)\n5. If on medication, must have been on the same type and dosage for at least 3 months.\n\nExclusion Criteria:\n\n1. Diagnosis of mania, psychosis, or bipolar disorder\n2. Impediments to TMS or MRI (i.e. metal implants in body)\n3. Prior electroconvulsive therapy or vagus nerve stimulation\n4. Diagnosis of Autism Spectrum Disorder.","9 Years","15 Years",{"count":58,"type":22},30,[60],"NA","Attention-Deficit\u002FHyperactivity Disorder (ADHD) is characterized by poor attention, impulsivity, hyperactivity and emotional-motivational dysregulation. Here, we will test if theta burst repetitive transcranial magnetic stimulation (rTMS) can reduce the symptoms of ADHD.",[29],[64,65],"Attention-Deficit\u002FHyperactivity Disorder (ADHD","Repetitive transcranial magnetic stimulation (rTMS)","2026-05-11",{"date":68,"type":39},"2026-05-14",{"date":70,"type":39},"2026-03-01",{"date":72,"type":22},"2027-12-31",{"name":74,"class":75},"University of Calgary","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":19,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":47},"100610333","phase-1-methylphenidate-to-address-attention-and-executive-deficits-among-children-with-sickle-cell-disease-100610333","NCT07226219","Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease","Pilot Trial of Stimulant Treatment to Address Attention and Executive Deficits Among Children With Sickle Cell Disease","Inclusion Criteria:\n\n* Diagnosed with SCD of any genotype\n* Enrolled on the institutional protocol: Sickle Cell Clinical Research Intervention Program (SCCRIP)\n* Between the ages of 8.0 and 17.9 years\n\n  \\*Included if performance measure, rating scale or diagnostic criteria met (within the past 2 years):\n* \\*Score at or below the 16th percentile on any 2 out of 4 performance measures:\n\n  * NIH Toolbox Flanker\n  * NIH Toolbox List Sorting\n  * NIH Toolbox Dimensional Change Card Sort Test (DCST)\n  * Wechsler Intelligence Scale for Children (WISC) -5\u002F Wechsler Adult Intelligence Scale (WAIS)-4 Digit Span Forward (DSF)\n* \\*Score at or above the 84th percentile on any 1 out of 2 parent rating scales:\n\n  * BRIEF-2 Global Executive\n  * BASC-3 Attention\n* \\*Have a documented diagnosis of attention deficit \u002F hyperactivity disorder (any subtype)\n* English as the primary language\n* Research participant and one parent willing to participate and provide consent\u002Fassent according to institutional guidelines\n* Negative pregnancy test\n\nExclusion Criteria:\n\n* Primary language other than English\n* Score below the 2nd percentile on the Wechsler Abbreviated Scale of Intelligence (WASI)-2 intelligence quotient (IQ) test\n* Uncontrolled seizures (seizure within the past 6 months)\n* Cardiomyopathy or known congenital structural cardiac defects\n* Stenotic valvular disease, left coronary artery stenosis, or history of myocarditis or pericarditis\n* History of heart arrhythmia including ventricular tachycardia, ventricular fibrillation, supraventricular tachycardia, QT prolongation or concomitant use of medications associated with QT prolongation\n* Two or more prior episodes of priapism\n* Blood pressure \\>95th percentile at the three most recent visits consecutively (i.e., \\>95th percentile reading at all three of the most recent hospital visits to St. Jude).\n\n  * If blood pressure is \\> 95th %ile compared to age-norms on the day of the baseline visit, a repeat blood-pressure reading will be performed both electronically and manually to confirm findings.\n* Stimulant medication within the past two weeks\n* Severe sensory loss\n* Previous adverse reaction to methylphenidate\n* Inability or unwillingness of research participant or legal guardian\u002Frepresentative to give written informed consent.\n* Currently prescribed another investigational medication.\n* Currently prescribed any of the following:\n\n  * Phenobarbital (anticonvulsant)\n  * Phenytoin (anticonvulsant)\n  * Primidone (anticonvulsant)\n  * Warfarin (anticoagulant)\n  * Antipsychotic medications\n  * Selective Serotonin Reuptake Inhibitor (SSRI) medications\n  * Tricyclic antidepressant (TCA) medications\n  * Vasopressor medications","8 Years",{"count":85,"type":22},72,[25],"The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects.\n\nThe study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not.\n\nPrimary Objective:\n\n• Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits.\n\nSecondary Objective:\n\n• Evaluate neurobehavioral and safety outcomes following MPH treatment.\n\nExploratory Objective:\n\n• Evaluate decision-making and determinants influencing methylphenidate utilization among parents.",[89,90,91,92],"Sickle Cell Disease","Executive Dysfunction","Cognitive Impairment","Attention Deficit\u002FHyperactivity Disorder (ADHD)",[94,31],"SCD","2026-04-22",{"date":97,"type":39},"2026-04-23",{"date":99,"type":39},"2025-11-25",{"date":101,"type":22},"2028-08",{"name":103,"class":75},"St. Jude Children's Research Hospital",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":18,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100622110","the-adhd-kids-study-for-children-9-12-years-of-age-100622110","NCT07379359","The ADHD Kids´ Study for Children 9-12 Years of Age","The ADHD Kids´ Study: Randomized Clinical Trial on the OutSMARTers Program and Individual Counseling for Children Aged 9-12 With ADHD","OutSmarters","Inclusion Criteria:\n\n* age: 9-12\n* have an ADHD diagnosis confirmed by a school psychologist\n* children need to be fluent in Icelandic\n* Parents need to be fluent in Icelandic or English\n\nExclusion Criteria:\n\n* Children need to have an IQ of 70 or higher (WISC-IV test or WPSSI-R test)",{"count":113,"type":22},100,[60],"The aim of the study is to compare the efficacy of The OutSMARTers program- an ADHD skills training group program for children aged 9-12 to customized individual counseling provided by a professional, The Kid Counseling Program. Approximately 100 children will be randomly assigned to either intervention or a small wait-list group who will after a five-week-waiting period receive either intervention. Following the intervention, parents, children, and teachers will evaluate the effects on communication skills, well-being, and emotional regulation.",[29],[118,119,120,121,122],"Intervention program for ADHD","Children","OutSMARTers Program","Skill building","Cognitive-behavioral therapy","NOT_YET_RECRUITING","2026-01-26",{"date":126,"type":39},"2026-01-30",{"date":128,"type":22},"2026-01-02",{"date":130,"type":22},"2029-10-01",{"name":132,"class":75},"University of Iceland",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100590472","phase-2-clinical-trial-to-investigate-the-safety-and-efficacy-of-two-dexamfetamine-sulfate-formulations-in-adults-with-adhd-and-moderate-to-severe-depression-100590472","NCT06967857","Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression","Randomized, Placebo-controlled Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression (DEXAD)","DEXAD","Inclusion Criteria:\n\n1. Diagnosis of attention deficit \u002F hyperactivity disorder (ADHD) (according to DSM-5 (fifth version of Diagnostic and Statistical Manual of Mental Disorders) or ICD (International Statistical Classification Of Diseases And Related Health Problems) guidelines) which started in childhood (at the age of \\\u003C12 years)\n2. Patient has a minimum ADHS-Diagnostische Checkliste-Q (ADHS-DC) total score of 32 at baseline (Visit (V) 0)\n3. Moderate to severe depression according to ICD-10 (depressive episode: Code F32; recurrent depressive disorder: Code F33) and with a Montgomery-Åsberg Depression Rating Scale (MADRS) score of \\>20 at baseline (V0)\n4. CGI-S ≥ 4 at baseline (V0)\n5. Patients receiving selective serotonin reuptake inhibitors (SSRIs) or Serotonin-norepinephrine reuptake inhibitors (SNRIs) (stable doses within the last 2 weeks before inclusion) (≤40 mg (es)citalopram, 50-200 mg sertraline, 75 - 300 mg venlafaxine extended release)\n6. Male or female patients ≥ 18 years and ≤ 65 at time of enrolment\n7. Patients with QTc interval within normal ranges (≤470 ms in males and ≤480 ms in females)\n8. Patient is either free of stimulant medication or who, after discussion with his \u002F her treating physician, is able and willing to discontinue the current psychotropic medication(s) for treatment of ADHD symptoms (specifically, methylphenidate, lisdexamfetamine, guanfacine or atomoxetine or any other medication approved for the treatment of ADHD) ) for the duration of the study, as well as is able and willing to discontinue all relevant co-medication according to exclusion criterion no. 20a-s for comorbid conditions during the clinical trial, if applicable\n9. Written informed consent and data protection declaration obtained prior to the initiation of any protocol required procedures\n10. Willing and able to comply to study procedures and study protocol\n\nExclusion Criteria:\n\n1. Current or a history of severe co-morbid symptoms such as psychotic symptoms, schizophrenia, bipolar disorders or manic episodes\n2. Current or recent history of substance abuse disorder within the last 6 months of clinical trial entry\n3. Patients with body mass index (BMI) \\\u003C 18.5 kg\u002Fm² or \\>35 kg\u002Fm²\n4. History of serotonin syndrome events\n5. History of seizures or use of anticonvulsant medication\n6. Any other uncontrolled psychiatric condition that requires medication or may interfere with trial participation\n7. Known symptomatic cardiovascular disease including structural abnormalities, moderate and severe hypertension (systolic blood pressure ≥160 mmHg, diastolic blood pressure ≥100 mmHg), heart failure, myocardial infarction, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, potentially life-threatening arrhythmias and channelopathies (diseases caused by ion channel dysfunction)\n8. Significant, in the discretion of the investigator, hepatic, gastrointestinal, renal, haematological or oncologic disorder\n9. Diagnosis of glaucoma, hyperthyroidism, pheochromocytoma or porphyria\n10. Diagnosis or family history of Tourette's syndrome or dystonia\n11. Pre-existing cerebrovascular disorders such as cerebral aneurysm, vascular abnormalities including vasculitis or stroke\n12. Immunodeficiency disorders (e.g. organ transplantation, Human Immunodeficiency Virus (HIV) infection)\n13. Known hypersensitivity to any of the ingredients of the trial medication, e.g. patients with known rare hereditary problems of fructose intolerance\n14. Males or females of reproductive potential not willing to use effective contraception (defined as PEARL index \\\u003C1 - e.g. contraceptive pill, intrauterine device (IUD)) during the study period (Screening to Follow-up)\n15. Pregnancy and lactation\n16. Participation in another interventional clinical trial during the trial and within the previous 30 days prior to trial start\n17. Patients who are institutionalised by court order or regulatory action\n18. Patients, who are members of the staff of the trial centre, staff of the sponsor or involved Clinical Research Organisation (CRO), the investigator him- \u002F herself or close relatives of the investigator\n19. Legal incapacity and\u002F or other circumstances rendering the patient unable to understand the nature, scope and possible impact of the clinical trial\n20. Current use of and use within the last 2 weeks before inclusion due to possible interactions with stimulants or SSRIs\u002FSNRIs and possible resulting or expected side effects:\n\n    1. Antipsychotics (such as chlorpromazine, haloperidol, thioridazine; except for quetiapine up to 100mg\u002Fday)\n    2. SSRIs and SNRIs daily doses of \\>40 mg (es)citalopram, \\>200 mg sertraline, \\>300 mg venlafaxine extended release\n    3. Monoamine oxidase inhibitors (MAO) inhibitors\n    4. tricyclic antidepressants\n    5. benzodiazepines (including Z-drugs)\n    6. atypical antidepressants (with an exception for daily doses of 100-300 mg trazodone)\n    7. Dopamine reuptake inhibitors (special restriction for bupropion)\n    8. antiarrhythmics (Class IA and III)\n    9. antibiotics (in particular macrolides and fluoroquinolones, linezolid)\n    10. opioids\n    11. hydroxychloroquine, chloroquine\n    12. ketoconazole\n    13. acetylsalicylic acid (dose up to 300 mg allowed)\n    14. diphenhydramine\n    15. apixaban\n    16. metoprolol\n    17. pregabalin\n    18. budesonide \u002F formoterol\n    19. albuterol \u002F salbutamol","18 Years","65 Years",{"count":144,"type":22},105,[26],"The indication of attention-deficit\u002Fhyperactivity disorder (ADHD) to be examined often occurs with other psychiatric disorders, and the majority of adults with ADHD have at least one psychiatric comorbidity in their lives. Depression is one of the most common comorbidities in patients with ADHD. The prevalence of comorbid depression in adults with ADHD is estimated to be as high as 50%.\n\nThere is evidence that stimulants such as dexamfetamine and methylphenidate lead to an improvement in sustained focused attention, working memory, and a variety of cognitive processes in the prefrontal cortex (PFC). In combination with the pharmacological effects of stimulants, such as the inhibition of monoamine oxidase, the increase in the concentration of noradrenaline in the PFC and dopamine in the striatum, dexamfetamine and methylphenidate could improve the treatment of depression in patients with major depressive disorder and comorbid ADHD.\n\nThis clinical trial will evaluate the safety and efficacy of DEX in two different formulations compared to placebo in adults with ADHD and moderate to severe depression. To ensure double blinding of the treatment, placebo will be administered in the form of tablets and capsules.",[29,148],"Depression - Major Depressive Disorder",[31,150,151],"Depression","Adults","2026-01-12",{"date":154,"type":39},"2026-01-13",{"date":156,"type":39},"2025-05-15",{"date":158,"type":22},"2026-12",{"name":160,"class":75},"Prof. Dr. Frank Behrens",2,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":23,"phases":174,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":194},"100616080","phase-4-treating-young-children-with-attention-deficit-hyperactivity-disorder-100616080","NCT07300956","Treating Young Children With Attention Deficit Hyperactivity Disorder","Comparing Medication Treatments for Neurodevelopmental Differences in Young Children on Rates of Beneficial Response","TYCA","Inclusion Criteria:\n\n1. Males or females 3 to 5 years of age, inclusive (e.g. children age 5 years, 11 months are eligible).\n2. Child has a confirmed diagnosis of moderate or severe Attention-Deficit\u002FHyperactivity Disorder (diagnostic code: F90.9) based on Diagnostic and Statistical Manual of Mental Disorders - 5th Edition (DSM-5) criteria, review of supportive evidence (caregiver interview, behavioral observations, Vanderbilt Attention-Deficit\u002FHyperactivity Disorder Rating Scale results, any school or daycare information provided by caregiver).\n3. Clinician-rated Clinical Global Impairment-Severity (see description below) rating of ≥4 (denoting moderate or greater impairment due to their Attention-Deficit\u002FHyperactivity Disorder symptoms).\n4. The child's clinician and caretakers have decided on or are considering initiating drug therapy (with either Methylphenidate or Guanfacine).\n5. Primary language is English or Spanish.\n\nExclusion Criteria:\n\n1. History of taking Methylphenidate or Guanfacine. Prior use of other Attention-Deficit\u002FHyperactivity Disorder medications or other psychotropic medications is allowed.\n2. Current use of other Attention-Deficit\u002FHyperactivity Disorder medications (e.g., amphetamines), other psychotropic medications (e.g., atypical antipsychotics or serotonin reuptake inhibitors), or centrally active depressants (such as phenothiazines, barbiturates, or benzodiazepines)\n3. Electronic Health Record documentation of moderate to severe global developmental delay (F88) or intellectual disability (F70), or a score of \\\u003C55 on the Vineland Adaptive Behavior Scales-3.\n4. Medical contraindications to taking Methylphenidate or Guanfacine, including cardiac risk factors (e.g. known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease), increased intraocular pressure, glaucoma, verbal tics, Tourette's Syndrome, psychosis","3 Years","5 Years",{"count":173,"type":22},370,[175],"PHASE4","This project will evaluate the effectiveness of Methylphenidate versus Guanfacine in treating Attention-Deficit\u002FHyperactivity Disorder (ADHD) in children aged 3 through 5 years (inclusive), as measured by clinician rating of global improvement.",[29],[179,180,181,182,183,184],"Attention-Deficit\u002FHyperactivity Disorder","Methylphenidate","Guanfacine","Preschool Children","Comparative Effectiveness","Prospective Study","2026-01-05",{"date":187,"type":39},"2026-01-07",{"date":189,"type":22},"2026-02",{"date":191,"type":22},"2030-07",{"name":193,"class":75},"Children's Hospital Medical Center, Cincinnati",5]